Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

CAPS Rating: 3 out of 5

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.


Player Avatar rickoshay14 (< 20) Submitted: 12/30/2012 12:51:05 PM : Outperform Start Price: $8.85 ARNA Score: -105.62

I find that Arena has done a great job in setting up Belviq to achieve it's market potential, which addresses a global problem and is huge, but Arena will do well because it continues to Partner and develop a larger pipeline. In addition, once Belviq has past many approval hurdles, there are many other opportunities for Belviq to address other large health issues. I believe that once Arena's Partners begin marketing, there will be no doubt that Arena will outperform for many years to come, provided that they are not bought out

Featured Broker Partners